Barry Paul, MD, on Improving CAR T-Cell Therapy Efficacy in Multiple Myeloma

Video

The assistant professor of Hematologic Oncology and Blood Disorders at Atrium Health discussed integrating CAR T therapy into treatment paradigms.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Barry Paul, MD, assistant professor, Division of Plasma Cell Disorders, Department of Hematologic Oncology and Blood Disorders, Atrium Health, to learn more about the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.

CAR-T cell therapy is an attractive option for both patients and physicians partly because it is typically administered as a single infusion and continues to expand and proliferate in the absence of continued administration, making reinfusion largely unnecessary. This contrasts with the traditional treatment of patients with multiple myeloma, which requires continuous rounds of chemotherapy to be administered until disease progression or tolerance is reached.

Researchers are still trying to optimize the efficacy of CAR T-cell therapy in clinical practice and are developing new methods to improve this. Identifying adjunctive therapies that allow CAR T-cell therapies to persist for longer could lead to a more robust patient response, Paul notes. Similarly, efforts to improve the sequencing of T-cell mediated therapies, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, could allow practitioners to identify the most effective treatment option for different patient populations. Both areas necessitate more research, Paul concluded.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.